Clinical Trial Update: A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs [Phase 1, Phase 2]

View source ↗

Summary

A randomized, double-blind Phase I/II trial comparing HLX01 to rituximab in patients with moderate to severe rheumatoid arthritis who have inadequate response t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• HLX01 (null)
• Rituximab (rituximab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Rheumatoid Arthritis | Phase 1, Phase 2 | Status: COMPLETED